| Document Date: 2015-03-16 01:05:14
Open Document File Size: 54,02 KBShare Result on Facebook
Company Sanofi-Aventis Australia Pty Ltd / CARE MS-I Genzyme Corporation / Sponsor’s Comment Genzyme / PBAC / CARE MS-II Genzyme Corporation / Genzyme / Sanofi company / / Country Australia / / Currency USD / / Event FDA Phase / Product Issues / Product Recall / / Facility Consumer Comments facility / / IndustryTerm fingolimod accounting / infection management / / MedicalCondition therapy Multiple sclerosis / disease / cognitive impairment / pain / progressive / chronic disease / fatigue / high disease activity / Relapsing-Remitting Multiple Sclerosis / multiple sclerosis / infection / MS / / Person Submission / / Position representative / / Product Rebif / concern / CAMMS03409 / Alemtuzumab / T2 / / Technology Trial ID Protocol / MRI / /
SocialTag |
7.10 ALEMTUZUMAB solution for infusion, 10 mg/ mL; Lemtrada®; Genzyme (Sanofi-Aventis Australia Pty Ltd). Purpose of Application